Donanemab Bests Aducanumab in Head-to-Head AD Trial ...Middle East

Medscape - News
Patients with early, symptomatic Alzheimer's disease had significantly better amyloid clearance and plaque reduction after 6 months of treatment with donanemab compared with aducanumab. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Donanemab Bests Aducanumab in Head-to-Head AD Trial )

Apple Storegoogle play

Also on site :